Chemical modifications in aggregates of recombinant human insulin induced by metal-catalyzed oxidation: covalent cross-linking via michael addition to tyrosine oxidation products.
about
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsProtein oxidation and peroxidationTitanium Implant Osseointegration Problems with Alternate Solutions Using Epoxy/Carbon-Fiber-Reinforced Composite.Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: potential implications for protein aggregation and immunogenicityFree-radical polymer science structural cancer model: a review.Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.Oxidation of therapeutic proteins and peptides: structural and biological consequences.Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.Metal-catalyzed oxidation of protein methionine residues in human parathyroid hormone (1-34): formation of homocysteine and a novel methionine-dependent hydrolysis reaction.Fluorogenic tagging methodology applied to characterize oxidized tyrosine and phenylalanine in an immunoglobulin monoclonal antibody.Chemical and Biophysical Characteristics of Monoclonal Antibody Solutions Containing Aggregates Formed during Metal Catalyzed Oxidation.Nanoparticulate Impurities Isolated from Pharmaceutical-Grade Sucrose Are a Potential Threat to Protein Stability.Purification and identification of high molecular weight products formed during storage of neutral formulation of human insulin.Free-radicals and advanced chemistries involved in cell membrane organization influence oxygen diffusion and pathology treatment.Identification of N-Terminally Truncated Derivatives of Insulin Analogs Formed in Pharmaceutical Formulations.
P2860
Q26738810-C4CAEE07-A1B6-4335-ADEA-3FA8148EF6ACQ26749487-D8801C3F-0D2F-4AF7-B9A3-5AA2EF7AC67CQ35018806-8722269B-1302-4B73-8788-28CBD253BCF1Q37078660-2F8EA6DD-A2BA-455D-B458-385EE1780578Q37287575-871E25EA-D092-414D-AD4F-223E6726CAB9Q38048706-608ECA28-16F3-40E6-A410-25C25EDEB8CCQ38142887-1B00B891-9720-483F-BB8F-0C80E5B18DF4Q38798188-8C8F74D7-EA10-468F-943F-D6E4356C903BQ43116396-68DE0B21-04B0-4268-93FC-E44F33F375F6Q44879644-D0C4B24F-B97C-4456-B001-BE4F1EB5578EQ46267230-E588F4B6-CFC1-4C01-B4CE-7D207C076E60Q46275499-B78A86EC-CD8E-4BF8-89BD-A4D104478EF8Q46787378-5E4562B5-C103-4A79-B47A-A34B25BD8335Q47152884-C7ADBCEF-3936-4942-9583-A69BA8E4B256Q55006528-77551747-FF98-4AF3-A083-D97B44ABB744
P2860
Chemical modifications in aggregates of recombinant human insulin induced by metal-catalyzed oxidation: covalent cross-linking via michael addition to tyrosine oxidation products.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Chemical modifications in aggr ...... o tyrosine oxidation products.
@ast
Chemical modifications in aggr ...... o tyrosine oxidation products.
@en
type
label
Chemical modifications in aggr ...... o tyrosine oxidation products.
@ast
Chemical modifications in aggr ...... o tyrosine oxidation products.
@en
prefLabel
Chemical modifications in aggr ...... o tyrosine oxidation products.
@ast
Chemical modifications in aggr ...... o tyrosine oxidation products.
@en
P2093
P2860
P1476
Chemical modifications in aggr ...... o tyrosine oxidation products.
@en
P2093
Christian Schöneich
Olivier Mozziconacci
Riccardo Torosantucci
Victor Sharov
Wim Jiskoot
P2860
P304
P356
10.1007/S11095-012-0755-Z
P577
2012-05-10T00:00:00Z